ArticleBrain and behavior2026
Serum AIM2 as a Prognostic Biomarker for Disease Severity and Delirium in Acute Pancreatitis: A Multicenter Prospective Cohort Study.
Article in Brain and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAbsent in melanoma 2 (AIM2) is implicated in inflammation, and delirium is a common complication following acute pancreatitis (AP). We investigated whether serum AIM2 levels are related to severity and delirium after AP.
methodsThis multicenter prospective cohort study included 349 patients with AP and 100 controls. According to a ratio of 7:3, patients were randomly assigned to study group (244 cases) and validation group (105 cases). Severity metrics included the acute physiologic and chronic health evaluation II (APACHE II), Ranson scale, computed tomography severity index (CTSI), and bedside index for severity in acute pancreatitis (BISAP). Severity correlation and delirium association were determined by using multifactorial analyses. Delirium-prediction model was verified in the validation group.
resultsSerum AIM2 levels were significantly higher in patients with AP than in controls. Serum AIM2 levels were independently correlated with the APACHE II scores, Ranson scores, BISAP scores, and CTSI scores. Serum AIM2 levels were linearly related to delirium risk after AP under the restricted cubic spline. Serum AIM2 levels, CTSI scores and BISAP scores were independently associated with delirium following AP. Serum AIM2 levels had predictive ability comparable to those of APACHE II, Ranson, BISAP, and CTSI scores. Delirium-prediction model integrating serum AIM2 levels, CTSI scores, and BISAP scores was stable and clinically valid by using a series of statistical approaches, whether in the study group or validation group.
conclusionsEnhanced serum AIM2 levels are tightly correlated with disease severity and efficiently predict delirium following AP, suggesting that serum AIM2 may be a potential biomarker of AP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.